{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:07:07Z","timestamp":1792692427246,"version":"4.5.0"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.sleep.2025.108743","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:07:48Z","timestamp":1766794068000},"page":"108743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Pharmacological management of insomnia with a focus on GABAA receptor positive allosteric modulators and orexin receptor antagonists"],"prefix":"10.1016","volume":"139","author":[{"given":"Chelsea","family":"Unger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0183-3816","authenticated-orcid":false,"given":"Kristi A.","family":"Kohlmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2025.108743_bib1","series-title":"International classification of sleep disorders","year":"2023"},{"key":"10.1016\/j.sleep.2025.108743_bib2","series-title":"Text rev.; DSM-5-TR)","article-title":"Diagnostic and statistical manual of mental disorders","year":"2022"},{"key":"10.1016\/j.sleep.2025.108743_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12072493","article-title":"Alliance for sleep clinical practice guideline on switching or deprescribing hypnotic medications for insomnia","volume":"12","author":"Watson","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.sleep.2025.108743_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14035","article-title":"The European insomnia guideline: an update on the diagnosis and treatment of insomnia 2023","volume":"32","author":"Riemann","year":"2023","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2025.108743_bib5","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1038\/s41598-023-36016-4","article-title":"The mortality risk of night-time and daytime insomnia symptoms in an older population","volume":"13","author":"Harvey","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.sleep.2025.108743_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.amjmed.2014.10.015","article-title":"Persistent insomnia is associated with mortality risk","volume":"128","author":"Parthasarathy","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.sleep.2025.108743_bib7","article-title":"Chronic Insomnia disorder across Europe: expert opinion on challenges and opportunities to improve care","volume":"11","author":"Ellis","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.sleep.2025.108743_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jsmc.2022.03.003","article-title":"Epidemiology of insomnia: prevalence, course, risk factors, and public health burden","volume":"17","author":"Morin","year":"2022","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.sleep.2025.108743_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2869.2000.00182.x","article-title":"Familial incidence of insomnia","volume":"9","author":"Bastien","year":"2000","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2025.108743_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.sleep.2022.06.020","article-title":"The prevalence and severity of insomnia symptoms during COVID-19: a global systematic review and individual participant data meta-analysis","volume":"100","author":"AlRasheed","year":"2022","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2025.108743_bib11","series-title":"An international study (RAND Europe Research Report RRA216","article-title":"The societal and economic burden of insomnia in adults","author":"Hafner","year":"2023"},{"key":"10.1016\/j.sleep.2025.108743_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","article-title":"Cost of disorders of the brain in Europe 2010","volume":"21","author":"Gustavsson","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib13","first-page":"S246","article-title":"The economic impact of insomnia in managed care: a clearer picture emerges","volume":"12","author":"Fullerton","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.sleep.2025.108743_bib14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1186\/s12889-023-16329-9","article-title":"The burden of untreated insomnia disorder in a sample of 1 million adults: a cohort study","volume":"23","author":"Grandner","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.sleep.2025.108743_bib15","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1080\/13696998.2024.2407631","article-title":"Epidemiology and burden of chronic insomnia disorder in Europe: an analysis of the 2020 National Health and Wellness Survey","volume":"27","author":"Chalet","year":"2024","journal-title":"J Med Econ"},{"key":"10.1016\/j.sleep.2025.108743_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.sleep.2025.108743_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000524400","article-title":"Benzodiazepines remain important therapeutic options in psychiatric practice","volume":"91","author":"Dubovsky","year":"2022","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.sleep.2025.108743_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.sleep.2025.108743_bib19","article-title":"Benzodiazepines","author":"Bounds","year":"2024","journal-title":"StatPearls (Internet)"},{"key":"10.1016\/j.sleep.2025.108743_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1212028","article-title":"Long-term use of benzodiazepines in chronic insomnia: a European perspective","volume":"14","author":"Soyka","year":"2023","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.sleep.2025.108743_bib21","series-title":"Health and social care finance directorate","article-title":"Quality prescribing for Benzodiazepines and z-drugs: guide for improvement 2024 to 2027","year":"2024"},{"key":"10.1016\/j.sleep.2025.108743_bib22","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00213-014-3457-x","article-title":"The behavioral pharmacology of zolpidem: evidence for the functional significance of alpha1-containing GABA(A) receptors","volume":"231","author":"Fitzgerald","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.sleep.2025.108743_bib23","article-title":"Progress in GABAA receptor agonists for insomnia disorder","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib24","first-page":"S31","article-title":"Insomnia management: a review and update","volume":"72","author":"Shaha","year":"2023","journal-title":"J Fam Pract"},{"key":"10.1016\/j.sleep.2025.108743_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsad083","article-title":"Benzodiazepine, Z-drug, and sleep medication prescriptions in male and female people with opioid use disorder on buprenorphine and comorbid insomnia: an analysis of multistate insurance claims","volume":"46","author":"Martin","year":"2023","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116329","article-title":"Exploring clinical applications and long-term effectiveness of benzodiazepines: an integrated perspective on mechanisms, imaging, and personalized medicine","volume":"173","author":"Chang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.sleep.2025.108743_bib27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","article-title":"Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis","volume":"400","author":"De Crescenzo","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.sleep.2025.108743_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12888-023-04793-x","article-title":"Prescribing Z-drugs in Greece: an analysis of the national prescription database from 2018 to 2021","volume":"23","author":"Siafis","year":"2023","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.sleep.2025.108743_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40265-024-02020-9","article-title":"Dimdazenil: first approval","volume":"84","author":"Syed","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.sleep.2025.108743_bib31","article-title":"The effects of benzodiazepine use and abuse on cognition in the elders: a systematic review and meta-analysis of comparative studies","volume":"11","author":"Liu","year":"2020","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.sleep.2025.108743_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3988\/jcn.2019.15.1.9","article-title":"Risk of dementia in long-term benzodiazepine users: evidence from a meta-analysis of observational studies","volume":"15","author":"He","year":"2019","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.sleep.2025.108743_bib33","article-title":"Benzodiazepine and \"Z-Drug\" dependence: data from a tertiary care center","volume":"19","author":"Shukla","year":"2017","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.sleep.2025.108743_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082933","article-title":"Should trazodone be first-line therapy for insomnia? A clinical suitability appraisal","volume":"12","author":"Pelayo","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.sleep.2025.108743_bib35","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/sleep\/33.11.1553","article-title":"Efficacy and safety of Doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia","volume":"33","author":"Krystal","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib36","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/sleep\/30.11.1555","article-title":"Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia","volume":"30","author":"Roth","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40263-014-0198-7","article-title":"Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials","volume":"28","author":"Winkler","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2025.108743_bib38","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40265-023-01859-8","article-title":"The comparative effectiveness and safety of insomnia drugs: a systematic review and network meta-analysis of 153 randomized trials","volume":"83","author":"Pan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.sleep.2025.108743_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2023.101746","article-title":"Efficacy and tolerability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis","volume":"68","author":"Yue","year":"2023","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2025.108743_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2023.101773","article-title":"Reply to Hertenstein et al. 's commentary on Yue et al.: efficacy and tolerability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis","volume":"69","author":"Yue","year":"2023","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2025.108743_bib41","article-title":"Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation","volume":"61","author":"Edemann-Callesen","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.sleep.2025.108743_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2019.02.017","article-title":"Efficacy and safety of melatonin for sleep onset insomnia in children and adolescents: a meta-analysis of randomized controlled trials","volume":"68","author":"Wei","year":"2020","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2025.108743_bib43","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2147\/NSS.S340944","article-title":"Melatonin treatment for pediatric patients with insomnia: is there a place for it?","volume":"14","author":"Rolling","year":"2022","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib44","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s00431-024-05556-w","article-title":"European expert guidance on management of sleep onset insomnia and melatonin use in typically developing children","volume":"183","author":"Bruni","year":"2024","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.sleep.2025.108743_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/children10071121","article-title":"Low doses of melatonin to improve sleep in children with ADHD: an open-label trial","volume":"10","author":"Checa-Ros","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.sleep.2025.108743_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1175372","article-title":"Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/joim.13406","article-title":"Hypocretins (orexins): the ultimate translational neuropeptides","volume":"291","author":"Jacobson","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.sleep.2025.108743_bib49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.sleep.2025.108743_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1168100","article-title":"Treatment strategy for insomnia disorder: japanese expert consensus","volume":"14","author":"Takaesu","year":"2023","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.sleep.2025.108743_bib51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-022-01719-x","article-title":"Correction to: daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.sleep.2025.108743_bib52","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.sleep.2025.108743_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40263-023-00994-w","article-title":"Correction to: daridorexant in insomnia disorder: a profile of its use","volume":"37","author":"Nie","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2025.108743_bib54","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40263-023-01020-9","article-title":"Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem","volume":"37","author":"Di Marco","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2025.108743_bib55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40801-021-00279-y","article-title":"Medical costs associated with insomnia treatment with suvorexant monotherapy in Japan: results from a retrospective cohort study using a large-scale claims database","volume":"9","author":"Uchiyama","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.sleep.2025.108743_bib56","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/13651501.2022.2101927","article-title":"Health care workers' mental health in the face of COVID-19: a systematic review and meta-analysis","volume":"27","author":"Ghahramani","year":"2023","journal-title":"Int J Psychiatr Clin Pract"},{"key":"10.1016\/j.sleep.2025.108743_bib57","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1007\/s12325-021-01891-8","article-title":"Changes in healthcare resource use and costs in commercially insured insomnia patients initiating suvorexant","volume":"38","author":"Kale","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.sleep.2025.108743_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/nu15173679","article-title":"Rethinking the role of orexin in the regulation of REM sleep and appetite","volume":"15","author":"Mogavero","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.sleep.2025.108743_bib59","doi-asserted-by":"crossref","first-page":"24353","DOI":"10.1073\/pnas.1907354116","article-title":"Distinct effects of orexin receptor antagonist and GABA(A) agonist on sleep and physical\/cognitive functions after forced awakening","volume":"116","author":"Seol","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sleep.2025.108743_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13902","article-title":"The orexin story and orexin receptor antagonists for the treatment of insomnia","volume":"32","author":"Muehlan","year":"2023","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2025.108743_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101573","article-title":"The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis","volume":"61","author":"Xue","year":"2022","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2025.108743_bib62","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cger.2021.04.003","article-title":"Insomnia: pharmacologic treatment","volume":"37","author":"Lou","year":"2021","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.sleep.2025.108743_bib63","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-0043-1768667","article-title":"Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis","volume":"81","author":"Rocha","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.sleep.2025.108743_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2868","article-title":"Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant","volume":"38","author":"Okino","year":"2023","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib65","first-page":"1296","article-title":"Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis","volume":"27","author":"McElroy","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.sleep.2025.108743_bib66","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin receptor antagonists as emerging treatments for psychiatric disorders","volume":"36","author":"Han","year":"2020","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.sleep.2025.108743_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1070522","article-title":"Dual orexin receptor antagonists for treatment of insomnia: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant","volume":"13","author":"Khazaie","year":"2022","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.sleep.2025.108743_bib75","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026678","article-title":"Pharmacological and non-pharmacological treatments for insomnia: a protocol for a systematic review and network meta-analysis","volume":"100","author":"Chun","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.sleep.2025.108743_bib76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/acps.13201","article-title":"Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis","volume":"142","author":"Samara","year":"2020","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.sleep.2025.108743_bib77","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s41999-022-00731-4","article-title":"Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review","volume":"14","author":"Capiau","year":"2023","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.sleep.2025.108743_bib78","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsab224","article-title":"Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem","volume":"45","author":"Ufer","year":"2022","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12877-022-02757-6","article-title":"Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing","volume":"22","author":"Scharner","year":"2022","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.sleep.2025.108743_bib80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/2045125317743651","article-title":"Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013","volume":"8","author":"Davies","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.1597","article-title":"Patient values and preferences regarding communicating risk versus benefit of benzodiazepine initiation: a cross-sectional survey study","volume":"6","author":"Chahal","year":"2023","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.sleep.2025.108743_bib82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00134-024-07762-4","article-title":"Benzodiazepine and z-drug prescribing in critical care survivors and the risk of rehospitalisation or death due to falls\/trauma and due to any cause: a retrospective matched cohort study using the UK clinical practice research datalink","volume":"51","author":"Mansi","year":"2025","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.sleep.2025.108743_bib68","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1871527320666210618103344","article-title":"Benzodiazepines and sleep architecture: a systematic review","volume":"22","author":"de Mendonca","year":"2023","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"10.1016\/j.sleep.2025.108743_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27186041","article-title":"A comprehensive review of daridorexant, a dual-orexin receptor antagonist as new approach for the treatment of insomnia","volume":"27","author":"Ziemichod","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.sleep.2025.108743_bib71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.14326\/abe.11.109","article-title":"Differences in EEG-based brain network activity during Non-REM sleep","volume":"11","author":"Ageno","year":"2022","journal-title":"Adv Biomed Eng"},{"key":"10.1016\/j.sleep.2025.108743_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2020.101332","article-title":"Effects of orexin receptor antagonism on human sleep architecture: a systematic review","volume":"53","author":"Clark","year":"2020","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2025.108743_bib73","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10072-023-06601-6","article-title":"Comparative efficacy and safety of lemborexant 5 mg versus 10 mg for the treatment of insomnia: a systematic review","volume":"44","author":"Habiba","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.sleep.2025.108743_bib74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40263-023-00987-9","article-title":"Daridorexant in insomnia disorder: a profile of its use","volume":"37","author":"Nie","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2025.108743_bib69","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s42761-021-00079-1","article-title":"Zolpidem maintains memories for negative emotions across a night of sleep","volume":"3","author":"Simon","year":"2022","journal-title":"Affect Sci"},{"key":"10.1016\/j.sleep.2025.108743_bib83","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40266-022-00977-4","article-title":"Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: a secondary analysis of a randomised placebo-controlled trial","volume":"39","author":"Fietze","year":"2022","journal-title":"Drugs Aging"},{"key":"10.1016\/j.sleep.2025.108743_bib84","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s10072-023-06626-x","article-title":"Correction to: comparative efficacy and safety of lemborexant 5 mg versus 10 mg for the treatment of insomnia: a systematic review","volume":"44","author":"Habiba","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.sleep.2025.108743_bib85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-term safety and tolerability of daridorexant in patients with insomnia disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.sleep.2025.108743_bib132","doi-asserted-by":"crossref","first-page":"309","DOI":"10.23736\/S0026-4806.25.09690-9","article-title":"Insomnia disorder","volume":"116","author":"Ferini-Strambi","year":"2025","journal-title":"Minerva Med"},{"key":"10.1016\/j.sleep.2025.108743_bib86","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsad272","article-title":"Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials","volume":"47","author":"Huang","year":"2024","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.64719\/pb.4429","article-title":"Suvorexant in the treatment of difficulty falling and staying asleep (Insomnia)","volume":"52","author":"Berger","year":"2022","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.sleep.2025.108743_bib88","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00228-022-03381-4","article-title":"Daridorexant for the treatment of insomnia disorder: findings and implications","volume":"78","author":"Dos Santos","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib89","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.5664\/jcsm.9150","article-title":"Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder","volume":"17","author":"Moline","year":"2021","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.sleep.2025.108743_bib90","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s10072-024-07326-w","article-title":"Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study","volume":"45","author":"Fernandes","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.sleep.2025.108743_bib91","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14656566.2020.1743265","article-title":"Selecting a pharmacotherapy regimen for patients with chronic insomnia","volume":"21","author":"Hassinger","year":"2020","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.sleep.2025.108743_bib92","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/10600280221143794","article-title":"Daridorexant: comprehensive review of A new oral agent for the treatment of insomnia","volume":"57","author":"Park","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.sleep.2025.108743_bib93","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1002\/pcn5.85","article-title":"Comparative efficacy and safety of suvorexant and lemborexant for insomnia treatment","volume":"2","author":"Hayashi","year":"2023","journal-title":"PCN Rep"},{"key":"10.1016\/j.sleep.2025.108743_bib96","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/00207454.2021.1995383","article-title":"Understanding the unmet needs in insomnia treatment: a systematic literature review of real-world evidence","volume":"133","author":"Campbell","year":"2023","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.sleep.2025.108743_bib97","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/CEOR.S406137","article-title":"Benzodiazepine usage, healthcare resource utilization, and costs among older adults treated with common insomnia medications: a retrospective cohort study","volume":"15","author":"Wickwire","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.sleep.2025.108743_bib99","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpsychires.2024.06.029","article-title":"Association between the use of orexin receptor antagonists and falls or fractures: a meta-analysis","volume":"176","author":"Pan","year":"2024","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.sleep.2025.108743_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174730","article-title":"Z-drugs and the risk of hip fracture: a systematic review and meta-analysis","volume":"12","author":"Donnelly","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.sleep.2025.108743_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093240","article-title":"Use of daridorexant among patients with chronic insomnia: a retrospective observational analysis","volume":"12","author":"Williams","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.sleep.2025.108743_bib101","article-title":"[Health-related quality of life in patients consuming benzodiazepine]","volume":"53","author":"Garcia Atienza","year":"2021","journal-title":"Aten Primaria"},{"key":"10.1016\/j.sleep.2025.108743_bib102","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clinthera.2022.03.002","article-title":"Insomnia treatment preferences among primary care patients","volume":"44","author":"Perez","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.sleep.2025.108743_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.116","article-title":"Benzodiazepine usage and patient preference for alternative therapies: a descriptive study","volume":"2","author":"Sake","year":"2019","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.sleep.2025.108743_bib94","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0000000000001561","article-title":"Abuse potential of lemborexant, a dual orexin receptor antagonist, compared with Zolpidem and suvorexant in recreational sedative users","volume":"42","author":"Landry","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib95","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/JCP.0000000000000516","article-title":"Assessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover study","volume":"36","author":"Schoedel","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib104","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and Zolpidem Tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.sleep.2025.108743_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108412","article-title":"Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia","volume":"169","author":"Yoshikawa","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.sleep.2025.108743_bib106","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.rmed.2014.12.010","article-title":"Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease","volume":"109","author":"Sun","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.sleep.2025.108743_bib107","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s41105-024-00548-7","article-title":"The effect of the initial administration of suvorexant on severe sleep apnea syndrome","volume":"23","author":"Mieno","year":"2025","journal-title":"Sleep Biol Rhythm"},{"key":"10.1016\/j.sleep.2025.108743_bib108","doi-asserted-by":"crossref","first-page":"eabn8238","DOI":"10.1126\/scitranslmed.abn8238","article-title":"Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper","volume":"14","author":"Huhn","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.sleep.2025.108743_bib109","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsac007","article-title":"A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women","volume":"45","author":"Rahman","year":"2022","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.sleep.2024.07.036","article-title":"Long-term safety and efficacy of daridorexant in Japanese patients with insomnia disorder","volume":"122","author":"Uchimura","year":"2024","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2025.108743_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph181910222","article-title":"Cognitive behavioral therapy and acceptance and commitment therapy for the discontinuation of long-term benzodiazepine use in insomnia and anxiety disorders","volume":"18","author":"Chapoutot","year":"2021","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.sleep.2025.108743_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2025.106823","article-title":"Efficacy and safety of lemborexant in patients with insomnia: a systematic review and meta-analysis","volume":"136","author":"Khan","year":"2025","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2025.108743_bib113","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/arclin\/acx120","article-title":"The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis","volume":"33","author":"Crowe","year":"2018","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.sleep.2025.108743_bib114","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000525988","article-title":"Cognitive functioning in long-term benzodiazepine users","volume":"28","author":"Zetsen","year":"2022","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.sleep.2025.108743_bib115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/sleep\/9.2.309","article-title":"Hypnotic residual effects of benzodiazepines with repeated administration","volume":"9","author":"Roehrs","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib116","article-title":"Short-term safety profile of zolpidem: objective measures of cognitive effects","volume":"12","author":"DeClerk","year":"2020","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.sleep.2025.108743_bib117","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/JCP.0b013e3182664eec","article-title":"A method to assess the dissipation of the [corrected] residual effects of [corrected] hypnotics: eszopiclone versus zopiclone","volume":"32","author":"Boyle","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18189720","article-title":"The association between use of benzodiazepine receptor agonists and the risk of obstructive sleep apnea: a nationwide population-based nested case-control study","volume":"18","author":"Hsu","year":"2021","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.sleep.2025.108743_bib119","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14399","article-title":"The efficacy and safety of dual orexin receptor antagonists in obstructive sleep apnea: a systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Yeh","year":"2025","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2025.108743_bib120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737175.2024.2328728","article-title":"Orexins and primary headaches: an overview of the neurobiology and clinical impact","volume":"24","author":"Stanyer","year":"2024","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.sleep.2025.108743_bib121","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","article-title":"Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial","volume":"80","author":"Yardley","year":"2021","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2025.108743_bib122","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1177\/02698811211035390","article-title":"Effects of benzodiazepine and orexin receptor antagonist on cognitive function revealed by auditory event-related potentials","volume":"35","author":"Shiga","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s44323-025-00025-5","article-title":"Dual orexin receptor antagonists as promising therapeutics for Alzheimer's disease","volume":"2","author":"Ragsdale","year":"2025","journal-title":"NPJ Biol Timing Sleep"},{"key":"10.1016\/j.sleep.2025.108743_bib124","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00787-021-01883-7","article-title":"Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review","volume":"32","author":"Besterman","year":"2023","journal-title":"Eur Child Adolesc Psychiatr"},{"key":"10.1016\/j.sleep.2025.108743_bib125","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11325-025-03453-6","article-title":"Suvorexant for the treatment of sleep disorders in children with severe cerebral palsy","volume":"29","author":"Koichihara","year":"2025","journal-title":"Sleep Breath"},{"key":"10.1016\/j.sleep.2025.108743_bib126","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1089\/cap.2016.0206","article-title":"Suvorexant for the treatment of insomnia in adolescents","volume":"27","author":"Kawabe","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.sleep.2025.108743_bib127","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41398-024-03087-4","article-title":"Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review","volume":"14","author":"Kishi","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.sleep.2025.108743_bib128","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/pcn.13730","article-title":"Initial treatment choices for long-term remission of chronic insomnia disorder in adults: a systematic review and network meta-analysis","volume":"78","author":"Furukawa","year":"2024","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.sleep.2025.108743_bib129","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13895","article-title":"Light therapy in insomnia disorder: a systematic review and meta-analysis","volume":"32","author":"Chambe","year":"2023","journal-title":"J Sleep Res"},{"key":"10.1016\/j.sleep.2025.108743_bib130","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1017\/S0033291722002616","article-title":"Treating postpartum insomnia: a three arm randomised controlled trial of cognitive behavioural therapy and light dark therapy","volume":"53","author":"Verma","year":"2023","journal-title":"Psychol Med"},{"key":"10.1016\/j.sleep.2025.108743_bib131","doi-asserted-by":"crossref","first-page":"eAO8058","DOI":"10.31744\/einstein_journal\/2022AO8058","article-title":"Physical exercise as a therapeutic approach for adults with insomnia: systematic review and meta-analysis","volume":"20","author":"D'Aurea","year":"2022","journal-title":"Einstein (Sao Paulo)"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945725024189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945725024189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:35:44Z","timestamp":1769258144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945725024189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":130,"alternative-id":["S1389945725024189"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2025.108743","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological management of insomnia with a focus on GABAA receptor positive allosteric modulators and orexin receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2025.108743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108743"}}